New Treatments Significantly Reduce Need for Pediatric Lung Transplants in Cystic Fibrosis
Recent advances in cystic fibrosis therapy have led to a substantial decline in the number of children requiring lung transplants, according to medical experts. Pediatric pulmonologists report that modulator therapies, which target the underlying genetic defect in cystic fibrosis, are transforming outcomes for young patients. These treatments improve lung function and reduce infections, delaying or eliminating the need for surgical intervention in many cases.
The shift has been particularly notable in specialized pediatric transplant centers, where teams once routinely prepared children for transplantation are now seeing fewer cases overall. However, the children who do require transplants tend to present with more complex medical histories, posing new challenges for clinical teams. This evolving landscape was highlighted by Dr. Christian Benden, a pediatric lung transplant specialist, during his presentation at the 46th annual meeting of the International Society for Heart and Lung Transplantation held in Toronto on April 22, 2026.
Cystic fibrosis, a genetic disorder affecting the lungs and digestive system, was once a leading indication for pediatric lung transplantation. Over the past two decades, the proportion of transplants performed for this indication has steadily declined, reflecting both the success of new therapies and changing referral patterns. Data from European transplant registries show that cystic fibrosis accounted for approximately 15.2% of all adult lung transplants between 1995 and mid-2018, a share that has continued to decrease in subsequent years.
In France, institutions such as the Necker Enfants Malades Hospital in Paris have played a central role in managing pediatric cystic fibrosis care, including post-transplant follow-up since January 2019. The hospital’s multidisciplinary team integrates cardiac and thoracic surgery, pediatric intensive care, pneumo-allergology, and specialized cystic fibrosis units to support patients throughout their treatment journey.
Experts emphasize that although the reduction in transplant volume is a positive development, it underscores the importance of continued innovation in therapies for patients who do not respond to current modulators. Ongoing research focuses on next-generation treatments, including gene editing and RNA-based approaches, aiming to address the remaining unmet needs in the cystic fibrosis population.
As of April 2026, no major changes to transplant listing guidelines for pediatric cystic fibrosis have been announced by international regulatory bodies. The next review of eligibility criteria is expected during the annual consensus meeting of the International Society for Heart and Lung Transplantation, scheduled for later in 2026.
We invite readers to share their experiences and insights in the comments below. How have advances in cystic fibrosis treatment impacted your family or community? Your perspective helps deepen the conversation around innovation and access in rare disease care.